Osama El Shamy

Dr. Osama El Shamy

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 June 2020 in Journal of the American Society of Nephrology
Verified
Journal Article
Open access
PDF file
OSOsama El Shamy
Osama El Shamy
NPNiralee Patel
Niralee Patel
MAMohamed Halim Abdelbaset
Mohamed Halim Abdelbaset
LCLinda Chenet
Linda Chenet
JTJoji Tokita
Joji Tokita
Jaime UribarriJaime Uribarri
Jaime Uribarri

17 May 2021 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
ACAili Cao
Aili Cao
JLJianhua Li
Jianhua Li
MAMorad Asadi
Morad Asadi
JBJohn M. Basgen
John M. Basgen
BZBingbing Zhu
Bingbing Zhu
LKLewis Kaufman
Lewis Kaufman
Dachshund homolog 1 (DACH1), a key cell-fate determinant, regulates transcription by DNA sequence–specific binding. We identified diminished Dach1 expression in a large-scale screen for mutations that convert injury-resistant podocytes into injury-susceptible podocytes. In diabetic kidney disease (DKD) patients, podocyte DACH1 expression levels are diminished, a condition that strongly correlates with poor clinical outcomes. Global Dach1 KO mice manifest renal hypoplasia and die perinatally. Podocyte-specific Dach1 KO mice, however, maintain normal glomerular architecture at baseline, but rapidly exhibit podocyte injury after diabetes onset. Furthermore, podocyte-specific augmentation of DACH1 expression in mice protects from DKD. Combined RNA sequencing and in silico promoter analysis reveal conversely overlapping glomerular transcriptomic signatures between podocyte-specific Dach1 and Pax transactivation-domain interacting protein (Ptip) KO mice, with upregulated genes possessing higher-than-expected numbers of promoter Dach1-binding sites. PTIP, an essential component of the activating histone H3 lysine 4 trimethylation (H3K4Me3) complex, interacts with DACH1 and is recruited by DACH1 to its promoter-binding sites. DACH1-PTIP recruitment represses transcription and reduces promoter H3K4Me3 levels. DACH1 knockdown in podocytes combined with hyperglycemia triggers target gene upregulation and increases promoter H3K4Me3. These findings reveal that in DKD, diminished DACH1 expression enhances podocyte injury vulnerability via epigenetic derepression of its target genes.

28 April 2020 in American Journal of Nephrology
Verified
Journal Article
Closed access
PDF file
OSOsama El Shamy
Osama El Shamy
HTHa Tran
Ha Tran
SSShuchita Sharma
Shuchita Sharma
CRClaudio Ronco
Claudio Ronco
MNMohanram Narayanan
Mohanram Narayanan
Jaime UribarriJaime Uribarri
Jaime Uribarri
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

1 July 2020 in Kidney Medicine
Verified
Journal Article
Open access
OSOsama El Shamy
Osama El Shamy
SSShuchita Sharma
Shuchita Sharma
JWJonathan Winston
Jonathan Winston
JUJaime Uribarri
Jaime Uribarri

1 January 2021 in Kidney Medicine
Verified
Journal Article
Open access
OSOsama El Shamy
Osama El Shamy
NMNitzy Munoz-Casablanca
Nitzy Munoz-Casablanca
SCSteven Coca
Steven Coca
SSShuchita Sharma
Shuchita Sharma
RLRobert Lookstein
Robert Lookstein
JUJaime Uribarri
Jaime Uribarri
Reports of the incidence of acute kidney injury (AKI) in patients with COVID-19 have varied greatly from 0.5% to as high as 39%, with onset generally within 7 days from time of admission1. The nature of the kidney insult is acute tubular necrosis, immune cell infiltration or rhabdomyolysis as demonstrated in autopsy reports2,3. Moreover, infection with COVID-19 has been associated with coagulation abnormalities4, as well as complement-mediated generalized thrombotic microvascular injury5. These patients have been found to have high D-dimer, fibrin degradation product and fibrinogen values, an elevated INR, normal PTT and normal platelet counts. Renal artery thrombosis is a rare condition, the most common cause of which is atrial fibrillation. However, bilateral completely occlusive renal artery thrombosis is even rarer. We present a case of a patient with COVID-19 on systemic anticoagulation who presented with a serum creatinine of 6.04mg/dL requiring the initiation of kidney replacement therapy and was found to have bilateral renal artery thrombosis.

30 December 2021 in Kidney360
Verified
Journal Article
Closed access
PDF file
Pattharawin PattharanitimaPattharawin Pattharanitima
Pattharawin Pattharanitima
OSOsama El Shamy
Osama El Shamy
Kinsuk ChauhanKinsuk Chauhan
Kinsuk Chauhan
ASAparna Saha
Aparna Saha
HWHuei Hsun Wen
Huei Hsun Wen
LCLili Chan
Lili Chan
Key Points: Increasing distances from the nearest dialysis provider was associated with increased utilization of peritoneal dialysis. Driving distance is more reflective of the patient experience than straight-line distance. Background: Accessibility to dialysis facilities plays a central role when deciding on a patient’s long-term dialysis modality. Studies investigating the effect of distance to nearest dialysis-providing unit on modality choice have yielded conflicting results. We set out to investigate the association between patients’ dialysis modality and both the driving and straight-line distances to the closest HD- and PD-providing units. Methods: All patients with ESKD who initiated in-center HD and PD in 2017, were 18–90 years old, and were on dialysis for ≥30 days were included. Patients in residence zip codes in nonconterminous United States or lived >90 miles from the nearest HD-providing unit were excluded. Results: A total of 102,247 patients in the United States initiated in-center HD and PD in 2017. Compared with patients on HD, patients on PD had longer driving distances to their nearest PD unit (4.4 versus 3.4 miles; P30 miles from the nearest HD unit were more likely to be on PD if the nearest PD unit was a distance equal to/less than that of the HD unit. PD utilization increased with increasing distance from patients’ homes to the nearest HD unit. No change in this association was found regardless of if the PD unit was farther from/closer than the nearest HD unit. This association was not seen with straight-line distance analysis. Conclusions: With increasing distances from the nearest dialysis-providing units (HD or PD), PD utilization increased. Using driving distance rather than straight-line distance affects data analysis and outcomes. Increasing the number of PD units may have a limited effect on increasing PD utilization.